Download Files:
RLY-2608
$650 – $2,100
Products Details
Product Description
– RLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Ka[1].
Web ID
– HY-153306
Shipping
– Room temperature
Molecular Formula
– C29H14ClF5N6O2
References
– [1]Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2.
CAS Number
– 2733573-94-7
Molecular Weight
– 608.91
SMILES
– O=C1N[C@@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– PI3K
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
